Making immigration policy today requires a tough-minded balance between hardheartedness and compassion.
People look at the monument at Friendship Park, near where the border separating Tijuana, Mexico, and San Diego meets the Pacific Ocean Thursday, Jan. 19, 2021, in Tijuana, Mexico. In the days before Joe Biden became president, construction crews worked quickly to finish Donald Trump s wall at an iconic cross-border park overlooking the Pacific Ocean that then-first lady Pat Nixon inaugurated in 1971 as symbol of international friendship. (AP Photo/Gregory Bull)
By Thomas L. Friedman | The New York Times
| April 15, 2021, 2:00 p.m.
After reading as much as I can about the latest surge in illegal immigration along our southern border, I’m still not clear how much is seasonal, how much is triggered by President Joe Biden’s announcement that he was halting construction of Donald Trump’s border wall and reviewing Trump’s asylum policies, and how much is just the lure of
We need a high wall with a big gate on the southern border
bdnews24.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bdnews24.com Daily Mail and Mail on Sunday newspapers.
Thomas L Friedman: We need high wall with big gate on southern border
startribune.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from startribune.com Daily Mail and Mail on Sunday newspapers.
Posted on 553
Aviceda Therapeutics, a late-stage, pre-clinical biotech company focused on developing the next generation of immuno-modulators by harnessing the power of glycobiology to manipulate the innate immune system and chronic, non-resolving inflammation, is announcing the composition of the Executive Team that will guide the company through ongoing development of breakthrough, first-in-class therapeutics and continued growth opportunities as a business entity.
Serving in key leadership roles on Aviceda’s Executive Leadership Team will be:
Mohamed Genead, MD, CEO & President,
David Callanan, MD, Chief Medical Officer,
Derek Kunimoto, MD, JD, Chief Operating Officer,
Michael Tolentino, MD, Chief Technology Officer, and
Christopher Scott, PhD, Chief Scientific Officer.